

76/SE/LG/2018/GBSL

29th May, 2018

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
Security Code : GUFICBIO

To,
Listing Department,
Bombay Stock Exchange Limited,
Phiroze Jeejabhoy Towers, Dalal Street,
Mumbai - 400 001
Security Code :509079

Dear Sir,

Sub.: Proceedings of the National Company Law Tribunal (NCLT) Convened Meeting of the Equity Shareholders of the Company held on Monday, May 28, 2018


Pursuant to the order dated March 21, 2018 passed by the Hon'ble National Company Law Tribunal, Mumbai bench, the Meeting of the Equity Shareholders of the Company was held on May 28, 2018 at 2.30 p.m. at Hotel Parle International, B. N. Agarwal Market, Next to Dinanath Mangeshkar Hall, Vile Parle (East), Mumbai - 400057, Maharashtra, India, to approve Scheme of Amalgamation (Merger by Absorption) of Gufic Stridden Bio-Pharma Private Limited with the Company.

You are requested to kindly take the same on record.

Thanking you

Yours faithfully

For Gufic Biosciences Limited



Ami Shah
Company Secretary & Compliance Officer



Encl.: As stated above.

PROCEEDINGS OF THE NATIONAL COMPANY LAW TRIBUNAL CONVENED
MEETING OF THE EQUITY SHAREHOLDERS OF THE COMPANY
HELD ON MONDAY, MAY 28, 2018

The National Company Law Tribunal (NCLT) convened Meeting of the Equity Shareholders of the Company ("Meeting") was convened and duly held on Monday, 28th May, 2018 at Hotel Parle International, B. N. Agarwal Market, Next to Dinanath Mangeshhkar Hall, Vile Parle (East), Mumbai - 400 057 as per Notice dated April 18, 2018 issued by the Company in this regard.


The meeting commenced at 2.30 P.M.

Mr. Jayesh P. Choksi, Chairman appointed by the NCLT for the said Meeting, chaired the meeting. The Chairman informed that the Meeting is convened pursuant to the Order of the Hon'ble NCLT, Mumbai bench passed on March 21, 2018 in the matter of Scheme of Amalgamation (Merger by Absorption) of Gufic Stridden Bio-Pharma Private Limited ("Transferor Company") with Gufic Biosciences Limited ("Transferee Company or "Company") and their respective shareholders.

As the requisite quorum was present, the Chairman called the meeting to order. All the Directors of the Company were present at the Meeting. The Company Secretary introduced the Board Members present on the dais one by one. She informed the members present that the Notice of the Meeting, the Explanatory Statement under Section 230(3), 232(2) and 102 of the Companies Act, 2013 read with the rules framed thereunder along with the other Annexures, were duly dispatched to the shareholders by e-mail and post. With the permission of the Members, the Notice convening the Meeting were taken as read.

The Chairman and Mr. Pranav J. Choksi, Chief Executive Officer and Director of the Company then briefed the Members about the background and rationale of the Scheme along with the details of valuation, fairness opinion and the Statutory/Regulatory Approvals received.

The Chairman informed the Members that as required under the Companies Act, 2013 read with the Companies (Compromises, Arrangements and Amalgamations) Rules, 2016 and the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, the Company had provided its shareholders the facility to cast their vote through postal ballot and remote e-voting system administered by the National Securities Depository Limited ("NSDL"). He further informed that the Company has provided facility for voting through polling papers to facilitate voting by those members who were present at the Meeting, either personally or by



Corp. Office : 1st, to 4th Floor, SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel.: (91-22) 6726 1000 Fax : (91-22) 6726 1068 Email : info@guficbio.com
CIN L65990MH1984PLC033519

proxy and who had not cast their vote earlier through remote e-voting and postal ballot on the resolution as set out in the Notice dated April 18, 2018.

The Chairman then informed that Mr. Gajanan D. Athavale, a Practicing Company Secretary, Mumbai (Membership No. FCS 9177) was appointed as the scrutinizer to conduct the postal ballot process, remote e-voting and Poll process in a fair and transparent manner. The Chairman informed the Members who were present at the Meeting but had not cast their votes by way of postal ballot or remote e-voting may cast their votes at the Meeting.

The Chairman then invited the Members to speak at the Meeting on the resolution proposed at the Meeting. The Members then raised their queries and grievances and clarifications were provided for the same to the members by the Chairman and Mr. Pranav J. Choksi, CEO & Director.

The Chairman further informed the members present that the consolidated results of the voting will be declared within 48 hours of the conclusion of the Meeting and will be available on the Company's website www.gufic.com and the same shall be communicated to the Stock Exchanges where the shares of the Company are listed.

After conclusion of the voting process the meeting ended with a vote of thanks to the Chair.


The meeting concluded at 05.30 p.m.

Kindly take the same on your records.

Thanking you,

Yours faithfully,

For Gufic Biosciences Limited



Ami N. Shah

Company Secretary & Compliance Officer

